Combination Product Human Factors Final Guidance In Clearance, OCP Says
Priorities from the Office of Combination Products
Executive Summary
The OCP presented its priorities for 2023 and beyond at the RAPS/AFDO Combination Products Summit on 8 November.
You may also be interested in...
Q&A Guidance Clarifies Human Factors Testing For Combination Products
A highly anticipated final guidance from the FDA on Human Factor Studies answers frequently asked questions about human factor studies when designing combination products.
Human Factors Guidance Provides Clarity On Data Necessary In Premarket Submissions
FDA released an updated human factors guidance document on 9 December clarifying the types of human factor data the agency wants to see in pre-market submissions.
Ophthalmic Drug Dispensers Being Reclassified In US As Combo Products Get Regulatory Leeway
US FDA gives 12 month grace period for ophthalmic products once regulated as drugs to comply with requirements for combination products and temporarily exempts lower-risk constituents. Guidance specifies changes agency is making in response to Genus Medical v. FDA decision.